Back to search results

Telehealth Coaching for Pancreatic Cancer Survivors and Caregivers

This study is looking at how telehealth self-management coaching sessions can improve the quality of life for people who have survived pancreatic cancer and their family caregivers. Pancreatic cancer and its treatments can cause many symptoms that affect how well people live. This study aims to see if these coaching sessions, which cover physical, emotional, social, and spiritual well-being, can help manage symptoms and support caregivers. You might be able to join if you are at least 18 years old, have metastatic pancreatic adenocarcinoma, and can read English or Spanish. The study will measure changes in your quality of life at the beginning and again three months after you start the program. The current status of this study is unclear, and it plans to enroll 136 participants.

Study design
This interventional study plans to enroll 136 participants to evaluate telehealth self-management coaching sessions.
What's involved
Participants will attend telehealth self-management coaching sessions and complete questionnaires and interviews.
Compensation
Not stated in the trial record.
Follow-up
Your quality of life will be measured at the start of the study and again three months after you are assigned to a group.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06524973

Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

Recruiting
NAAges 18+InterventionalSupportive care
City of Hope Medical Center
~136 participants
Updated 2025-11-10 on ClinicalTrials.gov
What's tested:TelemedicineCounselingBest PracticeQuestionnaire AdministrationInrweview

At a glance

Recruiting sites
1 of 22 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient reported quality of life (QOL)
Measured over At baseline and at 3 months post randomization

Conditions

Metastatic Pancreatic Adenocarcinoma

Explore related trials

Pancreatic Carcinoma

Where it's being run

22 sites across 1 states
California22

Study leadership

  • Vincent Chung, MD · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Vincent Chung, MD
[email protected]
626-359-8111
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

• PATIENT: Documented informed consent of the participant and/or legally authorized representative
Assent, when appropriate, will be obtained per institutional guidelines
PATIENT: Age: ≥ 18 years
PATIENT: Eastern Cooperative Oncology Group (ECOG) ≤ 2
PATIENT: Ability to read and understand English or Spanish for questionnaires
PATIENT: Subjects must have histologically or cytologically confirmed diagnosis of metastatic pancreatic adenocarcinoma who are within 8 weeks of initial diagnosis
FAMILY CARE GIVER: Documented informed consent of the participant and/or legally authorized representative
Assent, when appropriate, will be obtained per institutional guidelines
FAMILY CARE GIVER: Age: ≥ 18 years
FAMILY CARE GIVER: Ability to read and understand English or Spanish for questionnaires
FAMILY CARE GIVER: A family member or friend identified by the patient and defined as a person who knows the patient well and is involved in the patient's medical care

Exclusion

• An employee who is under the direct/ indirect supervision of the principal investigator (PI)/ a co-investigator/ the study manager
A direct study team member

What this trial measures

  • Patient reported quality of life (QOL)At baseline and at 3 months post randomization

    Patient reported quality of life will be assessed by the Functional Assessment of Cancer Therapy- Hepatobiliary (FACT-Hep) quality of life score. The primary analysis will be a treatment group comparison of the QOL at 3 months via linear regression model, with adjustment for baseline FACT-Hep score and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be transformed to approximate normality as appropriate.